Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 18:10:1365.
doi: 10.3389/fonc.2020.01365. eCollection 2020.

The Role of 68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Preoperative Lymph Node Staging in Intermediate/High Risk Patients With Prostate Cancer: A Diagnostic Meta-Analysis

Xiang Tu  1 , Chichen Zhang  1   2 , Zhenhua Liu  1 , Guohua Shen  3 , Xiaoai Wu  3 , Ling Nie  4 , Tiancong Chang  2 , He Xu  1 , Yige Bao  1 , Lu Yang  1 , Qiang Wei  1
Affiliations

The Role of 68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Preoperative Lymph Node Staging in Intermediate/High Risk Patients With Prostate Cancer: A Diagnostic Meta-Analysis

Xiang Tu et al. Front Oncol. .

Abstract

Purpose: To evaluate the accuracy of 68Ga-PSMA positron emission tomography/computerized tomography (PET/CT) for preoperative lymph node staging using histopathological results of pelvic lymph node dissection (PLND) as reference standard in patients with intermediate/high risk of prostate cancer. Material and Methods: A systematic search of PubMed, Embase, and the Cochrane Library was completed up to May 2020. We included studies investigating accuracy of 68Ga-PSMA PET/CT in primary lymph node staging before radical prostatectomy and PLND. The pooled sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), diagnostic odds ratio (DOR), and the summary receiver operating characteristic (SROC) curve with an area under the curve (AUC) were synthesized. Results: Eleven studies comprising 904 patients were identified. Based on per-patient analysis, the pooled sensitivity and specificity reached 0.63 (95% CI: 0.46-0.78) and 0.93 (95% CI: 0.88-0.96), respectively, with the DOR of 22 (95% CI: 10-47). An overall accuracy was revealed by the SROC curve with AUC of 0.91 (95% CI: 0.88-0.93). Using the lymph node as unit, the pooled sensitivity and specificity were 0.70 (95% CI: 0.49-0.85) and 0.99 (95% CI: 0.96-1.00), respectively. And the DOR reached 167 (95% CI: 40-695) with an AUC of 0.96 (95% CI: 0.94-0.98). The pooled PPV and NPV all reached above 0.8 on basis of per-patient or per-node analysis. Conclusions: 68Ga-PSMA PET/CT represented as a promising test for preoperative lymph node staging and patients without lymph node metastatic status can rarely be misdiagnosed. However, its sensitivity ought to be improved before forgoing PLND.

Keywords: PET/CT; lymph node dissection; meta-analysis; positron emission tomography; prostate cancer; prostate-specific membrane antigen.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of study selection.
Figure 2
Figure 2
SROC curves for the diagnostic accuracy of 68Ga-PSMA PET/CT on a per-patient analysis. SROC curves: summary receiver operating characteristic curves.
Figure 3
Figure 3
SROC curves for the diagnostic accuracy of 68Ga-PSMA PET/CT on a per-node analysis. SROC curves: summary receiver operating characteristic curves.
Figure 4
Figure 4
Risk of bias and applicability concerns graph for the included studies.
Figure 5
Figure 5
Deeks' funnel plots of publication bias.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. 10.3322/caac.21492 - DOI - PubMed
    1. Cary KC, Punnen S, Odisho AY, Litwin MS, Saigal CS, Cooperberg MR. Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project. Prostate Cancer Prostatic Dis. (2015) 18:149–54. 10.1038/pcan.2015.3 - DOI - PMC - PubMed
    1. Abdollah F, Suardi N, Gallina A, Bianchi M, Tutolo M, Passoni N, et al. Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center. Ann Oncol. (2013) 24:1459–66. 10.1093/annonc/mdt120 - DOI - PubMed
    1. Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, et al. . Predicting survival of patients with node-positive prostate cancer following multimodal treatment. Eur Urol. (2014) 65:554–62. 10.1016/j.eururo.2013.09.025 - DOI - PubMed
    1. Mottet N, van den Bergh RCN, Briers E, Bourke L, Cornford P, De Santis M, et al. . EAU - ESTRO - ESUR - SIOG guidelines on prostate cancer 2018. In: European Association of Urology Guidelines. 2018 Edition. Vol presented at the EAU Annual Congress Copenhagen 2018. Arnhem: EAU Guidelines Office; (2018). Available online at: http://uroweb.org/guidelines/compilations-of-all-guidelines/

Publication types